Amendment No. 7 to Schedule 13D for Viridian Therapeutics, Inc.

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC filed Amendment No. 7 to their Schedule 13D regarding their holdings in Viridian Therapeutics, Inc. The amendment reports that the Reporting Persons have voting and dispositive power over 16,025,330 shares of Common Stock, representing 15.14% of the outstanding shares. This includes 3,914,458 shares of Common Stock and 12,110,872 shares issuable upon conversion of Series A and Series B Preferred Stock. On October 23, 2025, Fund II purchased 454,545 shares of Common Stock in an underwritten public offering for $9,999,990.00. The shares were purchased for investment purposes, and Fund II entered into a lock-up agreement restricting the sale of shares for 60 days. The Reporting Persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.